Over 120 peer reviewed publications have assessed the use of SIR-Spheres® Y-90 resin microspheres for metastatic Colorectal Cancer (mCRC).
In addition to the studies outlined on previous pages, other RCTs have confirmed the efficacy of SIR-Spheres Y-90 resin microspheres when added to first-line chemotherapy for patients with mCRC (with improved Objective Response Rate [ORR] and Time to Progression [TTP]).1,2 One of these studies also showed a significantly increased OS with the addition of SIR-Spheres Y-90 resin microspheres to chemotherapy.1
Beyond the first-line use of SIR-Spheres Y-90 resin microspheres there are also multiple prospective studies and retrospective analyses which show positive effects of SIR-Spheres Y-90 resin microspheres on TTP/PFS (overall and liver) and OS when added as consolidation of first-line chemotherapy (i.e., in patients deemed unresectable 12–26 weeks after first-line chemotherapy),3 when combined with chemotherapy in patients who have already failed at least first-line chemotherapy,4,5 and in heavily pretreated patients who are chemorefractory and have failed standard of care.6-8 Several other single-arm studies investigated SIR-Spheres Y-90 resin microspheres as a salvage therapy and demonstrated median survival of approximately 10–12 months, which is an improvement on historical control data.8 As such, ESMO guidelines recommend Selective Internal Radiation Therapy (SIRT) in this setting.9
1 van Hazel GA et al. J Surg Oncol 2004; 88: 78-85.
2 Gray B et al. Ann Oncol 2001; 12: 1711-1720.
3 Sangro B et al. ASCO Gastrointestinal Cancers Symposium 2010; Abs. 250.
4 Lim L et al. BMC Cancer 2005; 5: 132.
5 van Hazel GA. et al. J Clin Oncol 2009; 27: 4089-4095.
6 Hendlisz A et al. J Clin Oncol 2010; 28: 3687-3694.
7 Seidensticker R et al. Cardiovasc Intervent Radiol 2012; 35: 1066-1073.
8 Bester L et al. J Vasc Interv Radiol 2012; 23: 96-105.
9 Van Cutsem E et al. Ann Oncol 2016 Jul 5; ePub: doi:10.1093/annonc/mdw235